南财智讯11月14日电，回盛生物公告，武汉统盛投资有限公司于近日解除质押4,200,000股，占其所持股 份比例5.07%，占公司总股本比例2.08%。本次解除质押后，武汉统盛投资有限公司累计质押股份数量 为2,000,000股，占其所持股份比例2.42%。上述质押股份未负担重大资产重组等业绩补偿义务。 ...

一、股东股份解除质押的基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次解除质 押股份数量 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 一致行动人 | （股） | 注 2 比例 | 注 1 比例 | | | | | 武汉统盛 投资有限 | 是 | 2,000,000 | 2.42% | 0.99% | 2024.03.07 | 2025.11.13 | 湖北银行 股份有限 | | 公司 | | | | | | | 公司武汉 武昌支行 | | 武汉统盛 | | | | | | | 湖北银行 | | 投资有限 | 是 | 2,200,000 | 2.66% | 1.09% | 2024.03.26 | 2025.11.13 | 股份有限 | | 公司 | | | | | | | 公司武汉 | | | | | | | | | 武昌支行 | | 合计 | | 4,200,000 | 5.07% | 2.08% | | | | 1、本次解除质押基本情况 ...

（编辑 袁冠琳） 证券日报网讯 回盛生物11月13日在互动平台回答投资者提问时表示，公司聚焦主业，持续做好日常经 营管理工作，力争为投资者创造更大的价值。公司对外积极开拓市场，对内提升经营管理水平，在销售 收入增长的同时，进一步优化生产成本，毛利率逐步改善，今年前三季度取得了较好的经营业绩，营业 收入与净利润实现了新突破。二级市场股价受宏观经济环境、市场波动、投资者预期和情绪等多种因素 的综合影响。 ...

证券日报网讯回盛生物（300871）11月13日在互动平台回答投资者提问时表示，公司控股股东的对外投 资情况与上市公司没有关系，不会对公司生产经营产生影响。 ...

Core Insights - The animal health sector experienced a slight increase of 0.14% on November 12, with *ST Lvkang leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance Summary - *ST Lvkang (002868) closed at 36.77, up 5.00% with a trading volume of 62,400 shares and a transaction value of 226 million [1] - Other notable performers included: - Qudongli (920275) at 10.76, up 3.86% [1] - Yongshun Biological (920729) at 10.15, up 1.81% [1] - Biological Shares (600201) at 10.76, up 1.22% [1] - Zhongmu Shares (600195) at 7.98, up 0.50% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 35.94 million from institutional investors, while retail investors contributed a net inflow of 20.57 million [2] - The capital flow for individual stocks showed: - KQ Bio (688526) had a net inflow of 7.99 million from institutional investors [3] - Biological Shares (600201) had a net inflow of 6.25 million from institutional investors [3] - However, KQ Bio (688526) also experienced a net outflow of 16.05 million from retail investors [3]

Core Viewpoint - The stock of Wuhan Kewen Biological Technology Co., Ltd. (回盛生物) has experienced fluctuations, with a year-to-date increase of 120.22% and recent trading activity indicating a slight decline. The company operates in the veterinary pharmaceuticals sector, focusing on the research, production, and sales of veterinary drugs and feed additives [1][2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 1.26 billion yuan, representing a year-on-year growth of 58.92%. The net profit attributable to shareholders reached 188 million yuan, showing a significant increase of 494.28% compared to the previous year [2]. - Cumulatively, since its A-share listing, the company has distributed a total of 236 million yuan in dividends, with 135 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 12, the stock price was 21.70 yuan per share, with a market capitalization of 4.39 billion yuan. The stock has seen a trading volume of 72.95 million yuan and a turnover rate of 1.65% [1]. - The company has appeared on the "龙虎榜" (a stock trading list) seven times this year, with the most recent appearance on April 9, where it recorded a net buy of -65.95 million yuan [1]. Shareholder Information - As of September 30, the number of shareholders stood at 21,200, a decrease of 10.03% from the previous period. The average number of circulating shares per shareholder increased by 11.15% to 9,566 shares [2].

Core Insights - The animal health sector experienced a 1.04% increase on November 11, with *ST Lvkang leading the gains [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Stock Performance - *ST Lvkang (002868) closed at 35.02, up 5.01% with a trading volume of 1196 lots and a transaction value of 4.1884 million yuan [1] - Other notable performers included: - Qudongli (920275) at 10.36, up 4.65% [1] - Yongshun Biological (920729) at 9.97, up 2.15% [1] - Biological Shares (600201) at 10.63, up 1.24% [1] - Plai Ke (603566) at 14.42, up 1.19% [1] Capital Flow - The animal health sector saw a net outflow of 2.5437 million yuan from institutional investors and 7.7575 million yuan from speculative funds, while retail investors had a net inflow of 10.3012 million yuan [1] - Specific stock capital flows included: - Biological Shares (600201) with a net inflow of over 9.2092 million yuan from institutional investors [2] - *ST Lvkang (002868) had a net inflow of 1.1031 million yuan from retail investors [2] - Huayi Biological (603718) experienced a net outflow of 4.1338 million yuan from institutional investors [2]

Core Viewpoint - The company has begun exporting certain raw pharmaceutical materials to Taiwan [1] Group 1 - The company is actively engaging in international trade by exporting raw materials [1]

Core Viewpoint - The company has begun exporting certain raw pharmaceutical materials to Taiwan [1] Group 1 - The company is actively engaging in international trade by exporting raw materials [1]

Investment Rating - Industry Rating: Outperform the market (maintained rating) [9] Core Views - The swine sector continues to experience losses, with an increasing number of culled sows, indicating a need to focus on the expected recovery in this sector [2][13] - The dairy and beef sectors are undergoing significant capacity reduction, with a potential turning point for milk prices anticipated [3][15] - The pet sector is witnessing a trend towards premiumization and the rise of domestic brands, reshaping the competitive landscape [4][16] - The poultry sector is facing challenges with breeding stock shortages and improving consumer demand for yellow chickens [5][18] - The seed industry is poised for a turnaround, with an emphasis on biotechnology and the commercialization of genetically modified crops [7][23] - The feed sector shows signs of recovery, with leading companies like Haida Group achieving revenue and profit growth [24][26] Summary by Sections Swine Sector - The industry continues to face losses, with the average price of live pigs at 12.02 CNY/kg, down 4.07% from the previous week [13] - The average market value per head for leading companies is at historical low levels, with Muyuan at 3000-3500 CNY/head and Wens at 2000-3000 CNY/head [14] - Recommended stocks include leading breeders like Muyuan and Wens, with additional focus on flexible stocks such as Shennong Group and Dekang Agriculture [14] Beef Sector - The price of beef cattle is showing signs of stabilization, with the average price for fattened bulls at 25.62 CNY/kg [15] - The dairy cow population has decreased by 8%, indicating a significant capacity reduction [15] - Companies with mother cow resources or those adopting a "milk-meat linkage" model are expected to have stronger profitability [15] Pet Sector - The Double Eleven shopping festival highlighted the resilience and structural upgrades in the pet food market, with domestic brands gaining market share [4][16] - Key recommendations include pet food brands like Guibao Pet and Zhongchong Co., with a focus on companies with technological advantages and comprehensive product lines [17] Poultry Sector - The white chicken sector is under pressure due to breeding stock shortages, with a focus on the impact of avian influenza on imports [18][19] - Yellow chicken prices are expected to improve due to supply constraints and increasing consumer demand [20] - Recommended stocks include leading companies like Shennong Development and Yisheng Biological [19] Seed Sector - The seed industry is expected to benefit from increased focus on food security and the commercialization of genetically modified crops [7][23] - Key recommendations include leading seed companies like Longping High-Tech and Dabeinong [23] Feed Sector - Haida Group is highlighted as a key player in the feed sector, with significant market share growth and revenue increases [24][26] - The overall feed market is expected to recover as smaller companies exit the market, leading to improved conditions for remaining players [24]